Q1 2023 EPS Estimates for Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reduced by Analyst

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Rating) – Zacks Research decreased their Q1 2023 EPS estimates for shares of Bayer Aktiengesellschaft in a research note issued to investors on Tuesday, March 14th. Zacks Research analyst E. Bagri now expects that the company will post earnings per share of $0.55 for the quarter, down from their previous estimate of $0.61. The consensus estimate for Bayer Aktiengesellschaft’s current full-year earnings is $1.96 per share. Zacks Research also issued estimates for Bayer Aktiengesellschaft’s Q2 2023 earnings at $0.59 EPS, Q3 2023 earnings at $0.48 EPS, Q4 2023 earnings at $0.27 EPS, FY2023 earnings at $1.89 EPS, Q1 2024 earnings at $0.32 EPS, Q2 2024 earnings at $0.88 EPS, Q3 2024 earnings at $0.43 EPS, Q4 2024 earnings at $0.45 EPS, FY2024 earnings at $2.08 EPS and FY2025 earnings at $2.28 EPS.

Get Bayer Aktiengesellschaft alerts:

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Rating) last posted its quarterly earnings results on Tuesday, February 28th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.02. The business had revenue of $12.25 billion during the quarter, compared to analysts’ expectations of $11.53 billion. Bayer Aktiengesellschaft had a net margin of 8.47% and a return on equity of 20.26%.

A number of other equities analysts have also recently commented on the stock. Morgan Stanley cut shares of Bayer Aktiengesellschaft from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 6th. JPMorgan Chase & Co. lowered shares of Bayer Aktiengesellschaft from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 3rd. Finally, Bank of America lowered shares of Bayer Aktiengesellschaft from a “buy” rating to a “neutral” rating in a report on Monday, December 5th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Bayer Aktiengesellschaft Stock Down 0.3 %

BAYRY opened at $14.92 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.16 and a quick ratio of 0.77. Bayer Aktiengesellschaft has a fifty-two week low of $11.41 and a fifty-two week high of $18.45. The company’s 50-day moving average is $15.45 and its 200 day moving average is $13.87.

Bayer Aktiengesellschaft Company Profile

(Get Rating)

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents.

See Also

• Get a free copy of the StockNews.com research report on Bayer Aktiengesellschaft (BAYRY)
• This Small Tech With Big Growth Prospects Is Nearing A Buy Point
• Don’t Chase FedEx Higher, Wait For The Pullback
• 3 Stocks For A Defensive Tech Portfolio 
• Milk the Dividends on These 3 Cash Cows
• Europe Raises Interest Rates, Should the Fed Follow?

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.